Download PDF
Thromb Haemost 2002; 88(05): 703-704
DOI: 10.1055/s-0037-1613288
Commentary
Schattauer GmbH

Avoiding Overanticoagulation: Knowing your Antibiotics

Trevor Baglin
1   Department of Haematology, Addenbrooke’s Hospital, Cambridge University Hospitals Trust, Cambridge, UK
› Author Affiliations
Further Information

Publication History

Received 25 June 2002

Accepted 29 June 2002

Publication Date:
08 December 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Visser L, Penning-van Beest F, Kasbergen A. et al. Overanticoagulation associated with combined use of antibacterial drugs and coumarin anticoagulants. Thromb Haemost 2002; 88: 705-10.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Makris M, Watson HG. The management of coumarin-induced over-anticoagulation. Br J Haematol 2001; 114 (02) 271-80.
    CrossrefPubMedGoogle Scholar
  • 3 van der Meer F, Rosendaal F, Vandenbroucke J, Briet E. Bleeding complications in oral anticoagulant therapy. Arch Intern Med 1993; 153: 1557-62.
    CrossrefPubMedGoogle Scholar
  • 4 Cannegieter S, Rosendaal F, Wintzen A, Van Der Meer F, Vandenbroucke J, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11-7.
    CrossrefPubMedGoogle Scholar
  • 5 Palareti G, Leali N, Coccheri S. et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996; 348: 423-8.
    CrossrefPubMedGoogle Scholar
  • 6 Eckman M, Levine H, Pauker S. Effect of laboratory variation in the prothrombin-time ratio on the results of oral anticoagulant therapy. N Engl J Med 1993; 329 (10) 696-702.
    CrossrefPubMedGoogle Scholar
  • 7 Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991; 07 (04) 403-22.
    CrossrefPubMedGoogle Scholar
  • 8 Holbrook A, Wells P, Crowther N. Pharmacokinetics and drug interactions with warfarin. In: Poller L, Hirsh J. Oral anticoagulants: Arnold. 1996: 30-48.
    Google Scholar
  • 9 Mannucci P. Genetic control of anticoagulation. Lancet 1999; 353: 688-9.
    CrossrefPubMedGoogle Scholar
  • 10 Baglin T. Avoiding overanticoagulation: pharmacogenomics or pragmatism?. Thromb Haemost 2001; 85 (05) 945-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Hauptmann J. Pharmacokinetics of an emerging new class of anticoagulant/antithrombotic drugs. A review of small-molecule thrombin inhibitors. Eur J Clin Pharmacol 2002; 57 (11) 751-8.
    PubMedGoogle Scholar
  • 12 Hopfner R. Ximelagatran (AstraZeneca). Curr Opin Investig Drugs 2002; 03 (02) 246-51.
    PubMedGoogle Scholar